Experts advising the FDA voted that there wasn’t enough evidence to show that an experimental ALS drug from Amylyx Pharmaceuticals works, throwing approval into doubt
Neuroscience experts advising the Food and Drug Administration found that a study didn’t provide sufficient evidence thatTheir 6-to-4 vote on Wednesday
sets up a new test for the FDA as it considers approving the latest experimental drug promising to slow the march of the debilitating neurodegenerative disease.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA advisers to review ALS drug funded by Ice Bucket ChallengeAdvocates are pushing for a positive recommendation from the panel, but a review by FDA scientists said data was lacking on the drug's effectiveness.
Read more »
ALS drug funded by Ice Bucket Challenge to be reviewed by FDAAdvocates are pushing for a positive recommendation from the panel, but a review by FDA scientists said data was lacking on the drug's effectiveness.
Read more »
FDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease.
Read more »
FDA skeptical of benefits from experimental ALS drugThe Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease.
Read more »
FDA panel narrowly sides against experimental ALS drugFederal health advisers have narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease
Read more »
FDA skeptical of benefits from experimental ALS drugThe drug from Amylyx Pharmaceuticals has become a rallying cause for patients with the deadly neurodegenerative disease ALS, their families and members of Congress who’ve joined in pushing the FDA to greenlight the drug.
Read more »